Stocks:
5,168
ETFs:
2,288
Exchanges:
11
Market Cap:
$65.78T
24h Vol:
$10.16B
Dominance:
MSFT:4.81%
Stocklytics Platform
Asset logo  AMGN
Amgen
AMGN
60 / 100
S&P500
$314.85arrow_drop_up0.09%$0.31

Performance History

Stocklytics logo
Key Stats
Open$314.10
Prev. Close$314.54
EPS7
Dividend$8.76
Next Earnings DateSep 9, 2024
Dividend Yield %2.88%
Market Cap$168.27B
PE Ratio44.76
LOWHIGH
Day Range311.89
316.67
52 Week Range211.71
329.72
Ratios
P/B Ratio22.99
Revenue$28.19B
Operating M. %13.33%
Earnings$6.71B
Earnings Growth %2.52%
EBITDA Margin %41.86%
ROE %72.57%
EPS7

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Financial Forecast

AI Price Prediction

line chart placeholder

Analyst Ratings

info
Analyst ratings for this stock instrument are based on analysts' assumptions and should not be solely relied upon for financial decisions.

Correlated Companies

PRICE$805.21
24H (%)arrow_drop_up2.81%
24H ($)$22.03
MARKET CAP$744.33B
PRICE$522.03
24H (%)arrow_drop_up0.92%
24H ($)$4.80
MARKET CAP$476.05B
PRICE$150.83
24H (%)arrow_drop_down0.28%
24H ($)-$0.43
MARKET CAP$364.05B
PRICE$130.77
24H (%)arrow_drop_down0.16%
24H ($)-$0.21
MARKET CAP$332.27B

About Amgen (AMGN)

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Sector
Healthcare
Industry
Drug Manufacturers—General
CEO
Mr. Robert A. Bradway
Headquarters
Thousand Oaks
Employees
25200
Exchange
NASDAQ
add Amgen  to watchlist

Keep an eye on Amgen

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help
What is the 52-week high and low for Amgen (AMGN)?

For Amgen (AMGN), the 52-week high is $329.72, which is 5.24% from the current price. The 52-week low is $211.71, the current price is 47.99% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help
What is Amgen 's (AMGN) price per share?

The current price per share for Amgen (AMGN) is $313.3. The stock has seen a price change of -$1.24 recently, indicating a -0.39% change. This reflects the stock's recent market performance and investor sentiment.

help
Is Amgen (AMGN) a growth stock?

Amgen (AMGN) has shown an average price growth of 0.41% over the past three years. It has received a score of 59 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Amgen as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help
What is Amgen (AMGN) stock price performance year to date (YTD)?

As of the latest data, Amgen (AMGN) has a year-to-date price change of 5.35%. Over the past month, the stock has experienced a price change of 15.22%. Over the last three months, the change has been 10.51%. Over the past six months, the figure is 18.07%. Looking at a longer horizon, the five-year price change stands at 86.06%.

help
Is Amgen (AMGN) a profitable company?

Amgen (AMGN) has a net income of $6.72B, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 70.02% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 13.33% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $28.19B, with a revenue growth rate of 7.09%, providing insight into the company's sales performance and growth. The gross profit is $19.74B. Operating income is noted at $7.9B. Furthermore, the EBITDA is $12.07B.

help
What is the market capitalization of Amgen (AMGN)?

Amgen (AMGN) has a market capitalization of $168.27B. The average daily trading volume is 2.15M, indicating the stock's liquidity and investor engagement.

News

email

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level